Most Read Articles
Christina Lau, 5 days ago
Progress in the treatment of rare cancers is named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Jackey Suen, 08 Jul 2016

Scientists have refined anti-CD19 chimeric antigen receptor (CAR) T cell therapy, an investigational treatment for advanced non-Hodgkin’s lymphoma, with initial results showing significantly higher response and survival rates than the standard repertoire.

Brentuximab vedotin: A CD30-positive targeted therapy in a heavily pretreated relapsed or refractory Hodgkin lymphoma

19 Sep 2018
Kanker darah, seperti leukemia, Hodgkin lymphona, non-Hodgkin lymphoma dan multiple myeloma
Brentuximab vedotin (ADCETRIS®; Takeda Pharmaceuticals) is an antibody-drug conjugate that selectively delivers monomethyl auristatin E, a very potent antimicrotubule agent,into CD30-positive tumour cells, leading to the disruption of the microtubule network. This results in cell cycle arrest and apoptotic death of the CD30-positive cells, making brentuximab vedotin a promising anticancer agent.6,7

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Christina Lau, 5 days ago
Progress in the treatment of rare cancers is named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Jackey Suen, 08 Jul 2016

Scientists have refined anti-CD19 chimeric antigen receptor (CAR) T cell therapy, an investigational treatment for advanced non-Hodgkin’s lymphoma, with initial results showing significantly higher response and survival rates than the standard repertoire.